Jefferies Financial Group Initiates Coverage on Krystal Biotech (NASDAQ:KRYS)

Stock analysts at Jefferies Financial Group began coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research report issued on Wednesday, MarketBeat.com reports. The firm set a “buy” rating and a $245.00 price target on the stock. Jefferies Financial Group’s target price points to a potential upside of 39.82% from the company’s previous close.

A number of other research firms also recently issued reports on KRYS. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $175.22 on Wednesday. Krystal Biotech has a 52 week low of $141.72 and a 52 week high of $219.34. The stock’s 50 day moving average price is $159.97 and its two-hundred day moving average price is $174.80. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 58.60 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the firm posted $0.30 earnings per share. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. On average, equities research analysts forecast that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Entropy Technologies LP acquired a new stake in Krystal Biotech during the 4th quarter worth approximately $548,000. Summit Trail Advisors LLC bought a new position in Krystal Biotech during the 3rd quarter worth $1,893,000. Swiss National Bank lifted its holdings in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after acquiring an additional 15,545 shares during the period. Finally, Citigroup Inc. grew its stake in shares of Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).